We have been successful in obtaining funding to the end of March 2025 to be able to continue with a programme of CF reviews and evidence syntheses to support guidelines. We would like to document our gratitude to the CF Foundation and the UK CF Trust for awarding us this grant. More details here.
We have just published an updated version of our review 'Nebuliser systems for drug delivery in cystic fibrosis' adding a total of 13 new studies, although five of these were previously listed as 'Awaiting classification'. Despite the inclusion of the new studies, our main conclusions have not changed and we found insufficient data to establish whether one nebuliser system is better than another overall. We could not find evidence for all systems and all types of medication used in CF care, although we did find that the newer technologies e.g. AAD and VMT have some advantages over conventional systems. Clinicians need to be aware of the variability in the performance of different nebuliser systems, compatibility with specific nebulised medication, and they must work with their patients to choose the best nebuliser system for each individual. Read more details here.
CF Australia have published the first four chapters of their updated 'Standards of Care for Cystic Fibrosis' document which cites two of our reviews. Click here to access the current version and stay updated with upcoming chapters.
Our review of gastro-intestinal issues 'Thinking outside the box: a review of gastrointestinal symptoms and complications in cystic fibrosis' was published in June 2023, read it here.
Learn about our contributions to the "Standards of care for CFTR variant-specific therapy for people with CF" here.
Learn about our collaboration with the JLA here.
|We would like to thank our funders the CF Foundation and the UK CF Trust.|